@article{0017c42f3c2744ab8af71e3322e87bbe,
title = "COGENT (COlorectal cancer GENeTics): An international consortium to study the role of polymorphic variation on the risk of colorectal cancer",
abstract = "It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.",
keywords = "Association, Colorectal cancer, Polymorphism",
author = "Tomlinson, {I. P.M.} and M. Dunlop and H. Campbell and B. Zanke and S. Gallinger and T. Hudson and T. Koessler and Pharoah, {P. D.} and I. Niittym{\"a}kix and S. Tuupanenx and Aaltonen, {L. A.} and K. Hemminki and A. Lindblom and A. F{\"o}rsti and O. Sieber and L. Lipton and {Van Wezel}, T. and H. Morreau and Wijnen, {J. T.} and P. Devilee and K. Matsuda and Y. Nakamura and S. Castellv{\'i}-Bel and C. Ruiz-Ponte and A. Castells and A. Carracedo and Ho, {J. W.C.} and P. Sham and Hofstra, {R. M.W.} and P. Vodicka and H. Brenner and J. Hampe and C. Schafmayer and J. Tepel and S. Schreiber and H. V{\"o}lzke and Lerch, {M. M.} and Schmidt, {C. A.} and S. Buch and V. Moreno and Villanueva, {C. M.} and P. Peterlongo and P. Radice and Echeverry, {M. M.} and A. Velez and L. Carvajal-Carmona and R. Scott and S. Penegar and P. Broderick and A. Tenesa and Houlston, {R. S.}",
note = "Funding Information: by the Dutch Cancer Society (UL2005-3247) and Fonds NutsOhra. In Hong Kong, work is supported by grants from the Michael and Betty Kadoorie Cancer Genetics Research Programme II and by the Bobby Moore Fund of Cancer Research UK. Work in Australia is conducted under the auspices of the Hilton Ludwig Cancer Metastasis Initiative and supported by a grant from the NHMRC (Project Grant 489418). In Japan, this work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The ESTHER and VERDI studies are supported by grants from the Baden W{\"u}rttemberg Ministry of Research, Science and Arts and the German Cancer Aid (Deutsche Krebshilfe, Grant M24/95/BR I). The Kiel cohort (POPGEN) is funded through the German Ministry of Education and Reserach through the POPGEN Biobank grant and the Colon Cancer Network of the German National Genome Research Network. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant no. 03ZIK012) and by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the {\textquoteleft}Center of Knowledge Interchange{\textquoteright} program of Siemens AG. MME, AV and LC-C have received funding from Funding Information: The work of UK groups is supported by grants from Cancer Research UK and the European Union. In Spain, work is supported by grants from the Instituto de Salud Carlos III, grants FIS 05/1006, 08/1359, 08/1635 and European Commission FP6 Food-CT-2006-036224 (VM). In Canada, work is supported by grants from Genome Canada (the ARCTIC Project), the National Cancer Institute of Canada (the CaRE Project) and the Ontario Institute for Cancer Research. In Finland, work is supported by grants from Academy of Finland (Finnish Centre of Excellence Program 2006-2011), the Sigrid Juselius Foundation, the Finnish Cancer Societies and by the European Union. The work of DFKS is supported by the German Genome Network (NGFNplus). In the Czech Republic, work is supported by GACR 310/07/1430. In Sweden, work is supported by grants from the Swedish Cancer Foundation and the Swedish Research Council. In Barcelona and Santiago (Epicolon), work is supported by grants from Fondo de Investigaci{\'o}n Sanitaria (FIS 04/1126, 05/2031, 05/0071, 08/0025, 08/1276), Xunta de Galicia (PGIDIT07PXIB9101209PR), Fundaci{\'o}n de Investigaci{\'o}n M{\'e}dica Mutua Madrile{\~n}a (CRP and SCB), Ministerio de Educaci{\'o}n y Ciencia (SAF 07-64873), Asociaci{\'o}n Espa{\~n}ola contra el C{\'a}ncer, Fundaci{\'o}n Olga Torres (SCB) and Acci{\'o}n Transversal contra el C{\'a}ncer (Instituto de Salud Carlos III). CIBERER and CIBEREHD are funded by the Instituto de Salud Carlos III. SCB is supported by a contract from the Fondo de Investigaci{\'o}n Sanitaria (CP 03-0070, Ministerio de Sanidad. Provision of genotyping is gratefully provided by Santiago de Compostela node of the Spanish National Genotyping Center (CeGen). In The Netherlands, work of RH is supported by the Dutch Cancer Society and the European Community, and the work of JTW, TvW, HM and PD is supported",
year = "2010",
month = jan,
doi = "10.1038/sj.bjc.6605338",
language = "Ingl{\'e}s",
volume = "102",
pages = "447--454",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",
}
